Exelixis' cabozantinib shows positive effect in late-stage thyroid cancer study

 

• Exelixis (NASDAQ:EXEL) is +3% on announcing results from Phase 3 trial, COSMIC-311,  evaluating cabozantinib (Cabometyx) in radioiodine-refractory differentiated thyroid cancer patients who have progressed after up to two prior vascular endothelial growth factor receptor targeted therapies.
• The study met the co-primary endpoint of demonstrating significant improvement in progression-free survival (PFS), compared to placebo, and showed that cabozantinib reduced the risk of disease progression or death by 78% at this planned interim analysis. The safety profile was consistent with that previously observed for cabozantinib.
• Given these results, the independent data monitoring committee for the study recommended to stop enrollment, unblind sites & patients as well as plans for a regulatory filing with the FDA in the near term.
• Detailed results will be submitted for presentation at a future medical conference.
• https://seekingalpha.com/news/3646159-exelixis-cabozantinib-shows-positive-effect-in-late-stage-thyroid-cancer-study